Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Accounts Payable: ¥262.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:605177 Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
52 GF Score
Price ¥24.73
GF Value ¥19.24
Valuation Modestly Overvalued
! 9 Warning Signs
View Full Analysis

What is Zhejiang East-Asia Pharmaceutical Co Accounts Payable?

Zhejiang East-Asia Pharmaceutical Co SHSE:605177 +0.16% 52 Accounts Payable is ¥262.3 Mil as of Jun. 2026. GuruFocus rates SHSE:605177 with a GF Score™ of 52/100 and a GF Value™ of ¥19.24 (Modestly Overvalued). The stock has 9 warning signs investors should review.

Zhejiang East-Asia Pharmaceutical Co's Accounts Payable for the quarter that ended in Jun. 2026 was ¥262.3 Mil.

Zhejiang East-Asia Pharmaceutical Co's quarterly Accounts Payable declined from Dec. 2025 (¥300.7 Mil) to Mar. 2026 (¥290.0 Mil) and declined from Mar. 2026 (¥290.0 Mil) to Jun. 2026 (¥262.3 Mil).

Zhejiang East-Asia Pharmaceutical Co's annual Accounts Payable increased from Dec. 2023 (¥281.0 Mil) to Dec. 2024 (¥388.4 Mil) but then declined from Dec. 2024 (¥388.4 Mil) to Dec. 2025 (¥300.7 Mil).

Zhejiang East-Asia Pharmaceutical Co Accounts Payable Related Terms

Zhejiang East-Asia Pharmaceutical Co Accounts Payable Historical Data

* Premium members only.

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang East-Asia Pharmaceutical Co Accounts Payable Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 187.35 276.60 280.99 388.44 300.74

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 305.11 273.19 300.74 290.04 262.27
SHSE:605177
52GF Score
Zhejiang East-Asia Pharmaceutical Co Ltd SHSE:605177
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang East-Asia Pharmaceutical Co Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of ¥262.3 Mil mean?
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Accounts Payable of ¥262.3 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors.
Is Zhejiang East-Asia Pharmaceutical Co's Accounts Payable too high?
Zhejiang East-Asia Pharmaceutical Co's current Accounts Payable is ¥262.3 Mil. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 52/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Accounts Payable compare to VRTX and REGN?
Zhejiang East-Asia Pharmaceutical Co's Accounts Payable of ¥262.3 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. Zhejiang East-Asia Pharmaceutical Co's current Accounts Payable is ¥262.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥19.24, compared to a current price of ¥24.73 — trading 28.5% above its estimated fair value. The current Accounts Payable is ¥262.3 Mil. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 52/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Accounts Payable is ¥262.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥24.73 is trading 28.5% above its estimated GF Value™ of ¥19.24. GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:605177:

  • Accounts Payable: ¥262.3 Mil
  • GF Value™: ¥19.24 vs. price of ¥24.73 (28.5% above fair value)
  • GF Score™: 52/100 with 9 warning signs

No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang East-Asia Pharmaceutical Co Business Description

Address No. 118, Laodong North Road, 23rd Floor, Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
52GF Score

Get the complete analysis for SHSE:605177

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥24.73
Price
¥19.24
GF Value